

5/4/10

CLINICAL RESEARCH PROTOCOL CONTINUING REVIEW APPLICATION PROTOCOL NO. OH95-C-N025 PRINCIPAL INVESTIGATOR (NIH Employee Name, Inst/Br, Address, Telephone and email): Arthur Schatzkin, MD. Dr. PH. NCI/NEB, 6120 executive blvd. Rockville, MD 301-594293 schatzka@mail.nih.gov

PROTOCOL TITLE: NIH-AARP Diet and Health Study

PROTOCOL STATUS: Renew -Recruitment of participants has not yet begun. Renew -Participants are currently being recruited or enrolled. Renew -No longer recruiting or enrolling participants, subject follow-up only. Renew -Participants have completed study; study and data analyses ongoing. Renew -Clinical Hold/Recruitment or enrollment of participants suspended. Terminate -Study closed. Participants have completed study. Recruitment and data analysis complete.

SUMMARY OF PROTOCOL ENROLLMENT (Aggregate): Only when the NIH is the coordinating site, provide totals and enrollment table for other site. Table with columns: NIH Site, Other Sites, Total. Rows: Accrual ceiling by IRB, New subjects accrued since last CR, Aggregate total accrued.

Are you currently recruiting healthy volunteers? No Yes Will the protocol involve adults unable to give informed consent? No Yes

Have analyses by sex, racial/ethnic subgroups been conducted for Phase 3 Clinical Trials as required? No Yes (answer a and b) N/A a. Have analyses been reported? No (explain in narrative) Yes b. Have significant differences been found? No Yes

Have any non-NIH Investigators or sites been added since the last review? No Yes (Identify the persons or sites and describe the collaboration in the summary report)

WITH THIS REVIEW, I AM REQUESTING A CHANGE TO THE FOLLOWING: \*Include Name, Inst/Branch, Telephone, Address, e-mail. Check box if an NIH Employee and initial line. Attach sheet if necessary.

PRINCIPAL INVESTIGATOR: Delete: Add\*: No

EXTRAMURAL ADJUNCT PRINCIPAL INVESTIGATOR: Delete: Add\*: No

MEDICAL ADVISORY INVESTIGATOR: Delete: Add\*: No

LEAD ASSOCIATE INVESTIGATOR: Delete: Add\*: No

RESEARCH CONTACT: Delete: Add\*: No

ASSOCIATE INVESTIGATOR(S): Delete: Add\*: No

IONIZING RADIATION USE (X-rays, e.g., CT; radioisotopes, e.g. PET, etc.) check all that apply: None Medically indicated Research indicated. Since the last review, Research usage HAS NOT changed. Research usage HAS changed. (Explain in summary report)

INVESTIGATIONAL NEW DRUG/DEVICE: None IND IDE \*If reporting more than one IND/IDE, list on attached sheet. FDA No. Name: Sponsor: Who is the manufacturer of the above entity?

Does the protocol involve a Tech Transfer Agreement? No Yes

Does the protocol involve a drug/device/product that may lead to you or the NIH receiving payment and/or royalties? No Yes (Append a statement of disclosure)

Have there been any amendments since the last review? No Yes (Describe briefly in the attached narrative.)

Have there been any changes in the informed consent process or documentation since the last review? No Yes (Describe in Summary report)

Have there been any changes in the subject population, recruitment or selection criteria since the last review? No Yes (Explain changes in the attached narrative.)

Have any unexpected complications or side effects been noted since the last review? No Yes (Identify and explain in the attached narrative.)

Have any subjects withdrawn from this study since the last IRB approval? No Yes (Discuss in the attached narrative.)

Has any information appeared in the literature, or evolved from this or similar research, that might affect the IRB's evaluation of the risk/benefit analysis of human subjects involved in this protocol? No Yes (Discuss in the attached narrative.)

Has the NIH IRP COI Guide been distributed to new NIH investigators? No Yes N/A

Has the NIH IRP COI Guide been distributed to new Non-NIH investigators? No Yes N/A

CONFLICTS OF INTEREST REVIEW? Date submitted to IC DEC: 3/16/10 Date cleared by IC DEC: 3/18/10

SIGNATURE RECOMMENDATION APPROVALS COMPLETION. Includes signatures and dates for Principal Investigator (Rashmi Sinha), Accountable Investigator (Rashmi Sinha), Branch/CC Dept. Head of Acc. Invest (Sheela Kalu), Clinical Director (Collin De), Chair, For Institutional Review Board (Nancy Potischman), and Protocol Specialist (Date: 4/27/10).

Expedited